Histac

Quick links to important sections

Histac

Selected form

Treatment option: Dyspepsia

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Histac

Property Description
Active Ingredient Ranitidine Hydrochloride
Primary Form Oral Tablet
Pharmacological Class Histamine H2-Receptor Antagonist (H2 Blocker)
General Purpose Gastric Acid Suppression
Origin Synthetic (Aralkylamines Derivative)

Histac is a synthetic medicinal product containing the active substance Ranitidine Hydrochloride, primarily functioning as a potent Histamine H2-Receptor Antagonist, commonly known as an H2 blocker. This classification signifies that the drug operates within the gastrointestinal therapeutic class, targeting the causes of acidity rather than neutralizing existing acid. The substance is an Aralkylamines Derivative, a compound whose efficacy is clinically recognized for its selective inhibition of acid secretion.


Composition, Active Ingredient, and Forms

The medication is formulated as a single-ingredient product where Ranitidine Hydrochloride is the sole active pharmaceutical ingredient. Ranitidine is highly soluble and is designed for rapid absorption after consumption. The medication is supplied in several key dosage form(s), most commonly as oral tablets and also as a sterile injection solution. The Histac brand has historically been positioned for broad use in adults and pediatric patients. The primary route of administration is oral for daily management, though the parenteral form allows for rapid systemic action in a clinical setting.


What is the General Purpose of Histac?

The general purpose of Histac is to achieve sustained acid-suppressing action in the stomach and upper gastrointestinal tract. It works by competitively inhibiting the H2 receptors on the parietal cells, preventing the signal that stimulates the massive release of Hydrochloric Acid (HCl) into the stomach lumen. By systematically reducing the volume of gastric acid secretion, the medicine's core benefit is to mitigate the corrosive effects of acid, thus promoting overall comfort and mucosal healing. This ability to suppress acid provides foundational support for its use in conditions related to gastric hyperacidity.

What side effects are possible with Histac?

Possible side effects and safety information

The safety profile of Histac (Ranitidine Hydrochloride) is based on classifications of documented adverse reactions organized by regulatory authorities according to frequency and body system involved. The vast majority of possible effects fall within the Uncommon and Rare frequency classifications.


Documented Adverse Reaction Categories

Adverse reactions are officially listed across multiple System Organ Classes (SOCs):

  • Gastrointestinal Disorders: Uncommon effects include abdominal pain, constipation, and nausea, which may tend to improve with continued treatment.
  • Nervous System Disorders: Documented effects include headache and dizziness. Reversible mental confusion, depression, and hallucinations have been reported, primarily in severely ill and older adults.
  • Hepatobiliary Disorders: Uncommon, transient, and reversible changes in liver function tests are listed. Rare events include various forms of hepatitis (with or without jaundice).
  • Blood and Lymphatic System Disorders: Very rare reports include severe events such as leucopenia, thrombocytopenia, agranulocytosis, and pancytopenia.

Serious Safety Considerations

Certain rare or very rare reactions are considered clinically significant and are highlighted in regulatory safety data:

  • Hypersensitivity: Serious hypersensitivity events, including anaphylactic shock, have been reported, sometimes after a single dose.
  • Cardiac Events: Very rare reports include bradycardia and A-V block.
  • Other Serious Reactions: Very rare instances of acute pancreatitis and acute interstitial nephritis are documented.

Context-Specific Safety Notes

Safety statements specify that the drug is contra-indicated for individuals with known hypersensitivity to the active substance. Caution is noted regarding use in patients with renal impairment, as plasma levels of the drug may be increased. Treatment may also mask symptoms associated with carcinoma of the stomach, which could delay diagnosis.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory documents define the overdose profile for the active ingredient, Ranitidine Hydrochloride, by listing specific systemic manifestations and mandatory emergency actions. An overdose primarily affects the Central Nervous System (CNS) and the Cardiovascular System.


Documented Overdose Manifestations

Physiological System Documented Presentation
CNS Effects Reversible confusion, agitation, hallucinations, dizziness, and somnolence (sleepiness).
Cardiovascular Effects Tachycardia (fast heartbeat), bradycardia (slow heartbeat), and arrhythmias.

CNS effects are reported predominantly in elderly and severely ill patients. Additionally, patients with impaired renal function are at an increased risk of toxicity due to potential drug accumulation.


Required Emergency Response

The regulatory-mandated action in the event of a suspected or known overdose is to contact a health care practitioner, hospital emergency department, or regional Poison Control Center immediately. This action is required even if the person currently appears asymptomatic. Immediate medical help is strictly necessary if the affected individual has collapsed, experienced a seizure, has trouble breathing, or cannot be awakened.

Overdose management procedures are symptomatic and supportive, and officially documented measures may include the use of activated charcoal and ECG monitoring. No specific antidote is known or documented for Ranitidine toxicity.

Therapeutic Uses of Histac

The medicine is relevant in contexts marked by increased discomfort or tension related to gastrointestinal issues. The core therapeutic domains and benefits are considered relevant for this class of medication.


Easing Symptoms of Heartburn and Acid Reflux

This domain addresses symptoms related to physical discomfort, which is commonly used to help with symptoms that interfere with daily comfort. The medicine contributes to improved comfort during periods of heightened symptoms by supporting relief for symptoms associated with acute or episodic changes. The medicine is applied across domains where additional symptomatic support is needed.


Support for Ulcers and Related Discomfort

This applies to conditions where symptoms create noticeable physiological strain, such as duodenal and gastric ulcers. The medicine supports patients during difficult episodes by easing distress and provides supportive relief when symptoms interfere with routine activities. It is relevant in contexts marked by increased discomfort or tension.

“The medicine provides support that helps ease the overall symptom burden.”

Quick Fact: Relevant for conditions involving episodic or fluctuating manifestations


Assistance with Gastroesophageal Reflux Disease (GERD)

The medication is applicable within clinical settings that involve acute or disruptive symptom patterns, and is used in conditions characterized by periods of heightened symptoms (GERD). It assists with maintaining functional stability and is applied in addressing recurrent or episodic manifestations.

Regulatory References

  1. NIH MedlinePlus Medical Encyclopedia

Eligibility and Restrictions for Use

Who Can and Cannot Use Histac?

Eligibility for Histac (Ranitidine) is strictly defined by regulatory documents based on contraindications, age, and patient health status, rather than therapeutic benefit.

Absolute Contraindications

Use is contraindicated (must not be used) in patients with a known hypersensitivity to ranitidine or any component of the formulation. The medicine is also strictly avoided in individuals with a history of acute porphyria.

Age-Related Eligibility

Age Group Eligibility Status
Adults (17+ years) Approved for use under standard conditions.
Pediatric (1 month–16 years) Safety and effectiveness are established for several indications.
Neonates (Under 1 month) Use is not established due to lower plasma clearance and insufficient data for dosing.
Geriatric (Older Adults) Use is permitted, but requires caution and potential dosage adjustment due to reduced renal function.

Conditional Use and Restrictions

Patients with severely impaired renal function require a formal dosage adjustment because the drug is primarily cleared by the kidneys. Caution must also be exercised in patients with hepatic dysfunction. Additionally, regulatory labels note that symptomatic relief from the medicine does not preclude the possibility of an underlying gastric malignancy, which must be excluded when a gastric ulcer is suspected.

Pregnancy and Lactation

Ranitidine is classified as Pregnancy Category B (US system); use is permitted only if clearly needed. The drug is secreted into human milk, and therefore, caution should be exercised when administered to a nursing mother.

What should I know about interactions with other medicines?

Histac's official interaction profile is defined by two primary mechanisms affecting how the body handles other substances: altered gastric pH and competition for the renal elimination pathway.

Documented Exposure Alterations

Interacting Substance/Class Official Interaction Statement Outcome
Acid-Dependent Drugs (e.g., Atazanavir, Ketoconazole) Reduced gastric acid secretion can impair absorption Reduced Exposure/Plasma Levels
Oral Midazolam, Triazolam, Glipizide Alters metabolism or absorption Increased Exposure/Plasma Levels
Procainamide (and N-acetylprocainamide) Reduced renal excretion due to competition for the organic cation transport system Increased Plasma Levels

Interaction Constraints and Cautions

Regulatory documentation highlights specific constraints for co-administration. Warfarin requires close monitoring of prothrombin time due to documented reports of altered coagulation time. For Sucralfate (high dose) and high-potency antacids, official documentation suggests potential for decreased Histac absorption, with the effect from Sucralfate being mitigated if administered after an interval of 2 hours. No clinically significant interaction with food or alcohol is documented in the label.

Histac is contraindicated in patients with a history of known hypersensitivity to the drug or components, and use is generally avoided in patients with a history of acute porphyria. A specific population note exists for patients with severe renal impairment ( Creatinine Clearance < 50 mL/min), where reduced clearance leads to documented elevated plasma concentrations and risk of accumulation.

Mechanism of Action

Histac (ranitidine) acts by targeting the histamine H2-receptors located on the gastric parietal cells to decrease gastric acid secretion. This mechanism is classified as competitive receptor antagonism.

Competitive Receptor Antagonism

Histac reversibly binds to the H2-receptors, thereby inhibiting the activation of the receptor by the endogenous neurotransmitter histamine. This occupancy prevents the normal receptor-mediated signaling sequence.

Suppression of Signaling Cascade

The interruption of H2-receptor signaling modifies an early molecular step in the acid-producing cascade. Specifically, the drug prevents the histamine-mediated activation of adenylate cyclase, leading to a subsequent failure to increase intracellular cyclic AMP (cAMP).

Modulation of Gastric Secretory Activity

This intracellular consequence results in a marked decrease in gastric acid secretion by the parietal cells. The process limits the impact of mediator activity on the proton pump, resulting in sustained suppression of secretory activity within the targeted pathway, particularly reducing basal and nocturnal acid production.

Dosage and Administration Information

How to Use Histac (Ranitidine)

The official administration of Histac is defined by regulatory guidelines, specifying the approved routes, standard doses, and conditions for use. The medicine is primarily administered orally as tablets or solution, though an Intravenous (IV) or Intramuscular (IM) injectable form is used when oral administration is not feasible or in specialized clinical settings.

Oral doses are to be taken without regard to meals and may be taken with water, as food does not significantly impair absorption. The frequency and dose vary based on the labeled condition and whether the treatment is acute or for maintenance.

Official Labeled Dosing Regimens

Usage Context Standard Adult Dosing (Oral) Frequency Pattern
Acute Ulcer Treatment 150 mg OR 300 mg Twice Daily (BID) OR Once Daily (QD) at bedtime
Ulcer Maintenance 150 mg Once Daily (QD) at bedtime
Erosive Esophagitis 150 mg Four Times Daily (QID)

Population and Procedural Instructions

Treatment courses are established for short-term use, often spanning 4 to 8 weeks for acute conditions, or for long-term maintenance that may extend up to one year. Dosage adjustments are a key procedural requirement for specific populations. For patients with severe renal impairment (creatinine clearance < 50 mL/min), the official dose frequency must be reduced to 150 mg every 24 hours.

For the injectable solution, strict dilution and infusion rate rules must be followed before administration in a clinical environment. If a scheduled dose of oral medication is missed, it should be taken as soon as possible, unless it is almost time for the next dose, in which case the missed dose should be skipped; doses should not be doubled.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Histac

Evidence for Use in Acid Reflux and Heartburn Symptoms (GERD)

Research examining Histac's role in contexts related to heartburn and acid reflux symptoms is based on numerous short-term, controlled clinical trials (RCTs) and subsequent analyses. These studies were applied in research contexts involving fluctuating or unstable symptoms, examining patient-reported experiences related to outcomes related to physical discomfort (heartburn, regurgitation). Researchers primarily focused on short-term symptom changes, with most treatment periods lasting about 4 to 8 weeks.

The trials also included patients with erosive esophagitis, an indication where studies monitored healing rates. Research describes patterns observed in the studies related to changes in symptoms and the physiological outcomes of acid suppression in the stomach. While studies exploring short-term symptom changes are available, long-term effects for chronic GERD management are not fully established.


Evidence for Use in Ulcer Management

Histac was evaluated in research exploring the short-term context of active duodenal and benign gastric ulcers. The evidence base includes a foundation of Randomized Controlled Trials and subsequent meta-analyses that examined clinical and healing outcomes. Studies also explored the role of Histac as a maintenance therapy in research exploring the recurrence of ulcers after initial healing. The primary outcomes related to systemic or functional imbalance that were monitored included the rate of endoscopic ulcer healing and the reported change in pain and discomfort.

Long-term studies monitored the frequency of ulcer recurrence, with follow-up durations sometimes extending over several years. Findings describe group patterns related to the maintenance of healing in the observed populations. The data for these indications were collected before the widespread implementation of current antibiotic protocols for H. pylori. The reported healing rates reflect the specific conditions under which the studies were conducted.


What Research Gaps and Uncertainty Remain

An honest review of the evidence highlights several areas where research is ongoing or where data are still limited. Most of the evidence for common indications, such as ulcers, is historical, having been conducted before major shifts in treatment protocols. Furthermore, while the medicine has been studied for acute conditions, follow-up durations were limited in many of the core trials for GERD management. Data for long-term outcomes and for specific, smaller subgroups experiencing fluctuating or unstable symptoms are often insufficient. Comparative evidence against other classes of acid-reducing medicines is also limited in current publications, meaning the historical findings provide context but not individual predictions about comparative effectiveness today.

Key Studies & References

  1. RANITIDINE TABLETS, USP: Full Prescribing Information and Clinical Studies Summary (covers GERD, Erosive Esophagitis, Ulcers, ZES, and Maintenance Therapy)
  2. Ranitidine: Use in Infants and Children (Pediatric use and dosing context)

Frequently Asked Questions (FAQ)

Common questions about Histac (FAQ)


Q: How quickly can a person generally expect to feel the effects of Histac?

A: According to official product information, symptomatic relief is described as occurring quickly, sometimes as soon as 30 to 60 minutes after a single dose. Peak concentration in the bloodstream is generally reached within one to three hours, which is consistent with the onset of acid suppression.


Q: What is the timeframe for how long Histac typically stays in the body?

A: The time it takes for Histac to be eliminated from the body is measured by its half-life, which is generally reported to be about 2.5 to 3 hours. This half-life describes the time required for the body to clear half of the drug from the plasma. This timeframe may be extended for certain groups, such as older adults, due to potential changes in renal function.


Q: Can Histac cause tiredness or drowsiness?

A: Regulatory documents list side effects that involve the central nervous system, including somnolence, which is the medical term for drowsiness or sleepiness. Dizziness is also listed as a possible adverse effect. Official information includes notes on caution related to these types of effects.


Q: Are there any serious side effects associated with Histac that are listed in official documents?

A: Official safety data highlights that serious adverse events, while rare or very rare, have been reported. These include severe hypersensitivity reactions, such as anaphylactic shock, and certain cardiac events, like changes in heart rhythm. Official documentation describes these events as possible occurrences.


Q: Can Histac be used by older adults?

A: Use of Histac is permitted in older adults, but regulatory caution is advised due to potential age-related reduced kidney function. Older adults may also show increased sensitivity to some central nervous system effects, such as confusion. The potential for dosage adjustment is noted for this population.


Q: What research has been done on Histac?

A: Research on the medicine includes extensive short-term, controlled clinical trials that examined its effects for specific conditions like peptic ulcers and gastroesophageal reflux disease (GERD). More recent research has focused on the safety profile and chemical stability of the active ingredient, including the evaluation of potential impurities.


Q: Is it normal to have a headache when starting Histac?

A: Headache is listed in official documentation as a documented adverse reaction that has been reported by some patients. The documented headache effect is sometimes reported to be severe.


Q: Does taking Histac affect my ability to drive?

A: Official information notes that some documented side effects, such as dizziness or blurred vision, could potentially impair a person’s ability to drive or operate complex machinery. Regulatory warnings mention that caution is recommended if these effects occur.


Q: Is it considered safe to take Histac every day?

A: Labeled dosing regimens include directions for daily use for both acute treatment and long-term maintenance therapy. Official guidance specifies that long-term use is typically managed under the supervision of a healthcare professional.


Q: What is the expected duration of treatment with Histac for common conditions?

A: The course of treatment is established for different use contexts. This includes short-term use, often spanning 4 to 8 weeks for acute conditions, or for long-term maintenance that may extend up to one year to prevent the recurrence of ulcers.


Q: What is the difference between Histac and famotidine?

A: Both medicines belong to the same pharmacological class, known as H2-receptor antagonists, and share the primary purpose of suppressing gastric acid. While they have similar roles and mechanisms, they are distinct chemical compounds with differences in their exact molecular structure and physical characteristics.


Q: Why would a doctor prescribe Histac instead of a different medicine for stomach issues?

A: Histac is an H2 blocker whose labeled purpose is to achieve sustained acid-suppressing action by directly targeting the receptors on the parietal cells in the stomach. The medicine is officially approved for specific conditions like ulcers and acid reflux, and its use is supported by its documented mechanism of action.


Q: Are there common skin reactions mentioned with Histac use?

A: Official documentation lists skin rash as a rare adverse effect. Serious skin reactions which may involve blistering have been reported in very rare instances. Additionally, hypersensitivity reactions can manifest as skin symptoms like hives or a rash.


Q: Is Histac available over-the-counter or is it prescription-only?

A: Historically, the medicine has been available in various countries in both prescription forms (typically higher doses) and over-the-counter (OTC) forms (typically lower doses) for different indications.


Q: Is Histac used for preventing stomach issues?

A: Yes, official documentation includes use in the context of maintenance therapy for specific conditions. The medicine is officially used in the context of maintenance therapy for conditions such as ulcers, following a period of initial healing.


Q: Are there any special dietary restrictions described when using Histac?

A: The medicine is generally noted to be taken without regard to meals. Specific safety guidance has addressed the potential for interactions with certain nitrite-containing foods (such as processed meats). This was noted as a consideration related to the product’s chemical stability.


Q: Can Histac cause changes in mood?

A: Regulatory documents list rare reports of central nervous system effects, including reversible mental confusion, depression, agitation, and hallucinations. These mood and mental changes have been predominantly noted in severely ill and older adult patients.

How should Histac be stored and disposed of?

How to Store and Dispose of Histac (Ranitidine)

Official regulatory guidance from the FDA has requested the immediate withdrawal of all ranitidine products, shifting the primary instruction from storage to disposal.

Prior Storage Conditions

Previously, Histac required storage at room temperature, typically below 30 C (86 F), protected from light and moisture. The medication had to be kept in its original, tightly closed container and strictly out of the sight and reach of children.

Mandatory Disposal Instructions

Consumers are instructed to stop taking any unused Histac immediately. The official disposal method is: do not flush down the toilet. Instead, mix the product with an undesirable substance (such as dirt or coffee grounds), place the mixture in a sealed container, and dispose of it in the household trash. All personal information on the label must be scratched out before discarding the packaging.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Histac found in:

A-Z Index: